OPRX Quote, Financials, Valuation and Earnings

Amedisys has a net margin of -0.24% compared to OptimizeRx's net margin of 10.26%. OptimizeRx's return on equity of -16.71% beat Amedisys's return on equity of 7.55%.

OptimizeRx has a consensus price target of $10.33, signalling upside risk potential of 19.32%. On the other hand Amedisys has an analysts' consensus of $96.17 which suggests that it could grow by 1.76%. Given that OptimizeRx has higher upside potential than Amedisys, analysts believe OptimizeRx is more attractive than Amedisys.

OptimizeRx has a beta of 1.179, which suggesting that the stock is 17.909% more volatile than S&P 500. In comparison Amedisys has a beta of 0.890, suggesting its less volatile than the S&P 500 by 11.035%.

OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amedisys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx pays -- of its earnings as a dividend. Amedisys pays out -- of its earnings as a dividend.

OptimizeRx quarterly revenues are $32.3M, which are smaller than Amedisys quarterly revenues of $594.8M. OptimizeRx's net income of -$78K is lower than Amedisys's net income of $61M. Notably, OptimizeRx's price-to-earnings ratio is -- while Amedisys's PE ratio is 34.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 1.72x versus 1.32x for Amedisys. Usually stocks with elevated PS ratios are considered overvalued.

Health Catalyst has a net margin of -0.24% compared to OptimizeRx's net margin of -25.97%. OptimizeRx's return on equity of -16.71% beat Health Catalyst's return on equity of -19.29%.

OptimizeRx has a consensus price target of $10.33, signalling upside risk potential of 19.32%. On the other hand Health Catalyst has an analysts' consensus of $8.23 which suggests that it could grow by 100.67%. Given that Health Catalyst has higher upside potential than OptimizeRx, analysts believe Health Catalyst is more attractive than OptimizeRx.

OptimizeRx has a beta of 1.179, which suggesting that the stock is 17.909% more volatile than S&P 500. In comparison Health Catalyst has a beta of 1.435, suggesting its more volatile than the S&P 500 by 43.508%.

OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Health Catalyst offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx pays -- of its earnings as a dividend. Health Catalyst pays out -- of its earnings as a dividend.

OptimizeRx quarterly revenues are $32.3M, which are smaller than Health Catalyst quarterly revenues of $79.6M. OptimizeRx's net income of -$78K is higher than Health Catalyst's net income of -$20.7M. Notably, OptimizeRx's price-to-earnings ratio is -- while Health Catalyst's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 1.72x versus 0.80x for Health Catalyst. Usually stocks with elevated PS ratios are considered overvalued.

Humana has a net margin of -0.24% compared to OptimizeRx's net margin of -2.37%. OptimizeRx's return on equity of -16.71% beat Humana's return on equity of 7.25%.

OptimizeRx has a consensus price target of $10.33, signalling upside risk potential of 19.32%. On the other hand Humana has an analysts' consensus of $307.01 which suggests that it could grow by 16.12%. Given that OptimizeRx has higher upside potential than Humana, analysts believe OptimizeRx is more attractive than Humana.

OptimizeRx has a beta of 1.179, which suggesting that the stock is 17.909% more volatile than S&P 500. In comparison Humana has a beta of 0.624, suggesting its less volatile than the S&P 500 by 37.637%.

OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humana offers a yield of 1.34% to investors and pays a quarterly dividend of $0.89 per share. OptimizeRx pays -- of its earnings as a dividend. Humana pays out 35.71% of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

OptimizeRx quarterly revenues are $32.3M, which are smaller than Humana quarterly revenues of $29.2B. OptimizeRx's net income of -$78K is higher than Humana's net income of -$693M. Notably, OptimizeRx's price-to-earnings ratio is -- while Humana's PE ratio is 26.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 1.72x versus 0.27x for Humana. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of -0.24% compared to OptimizeRx's net margin of 4.47%. OptimizeRx's return on equity of -16.71% beat Option Care Health's return on equity of 14.93%.

OptimizeRx has a consensus price target of $10.33, signalling upside risk potential of 19.32%. On the other hand Option Care Health has an analysts' consensus of $38.44 which suggests that it could grow by 16.85%. Given that OptimizeRx has higher upside potential than Option Care Health, analysts believe OptimizeRx is more attractive than Option Care Health.

OptimizeRx has a beta of 1.179, which suggesting that the stock is 17.909% more volatile than S&P 500. In comparison Option Care Health has a beta of 1.074, suggesting its more volatile than the S&P 500 by 7.353%.

OptimizeRx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx pays -- of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend.

OptimizeRx quarterly revenues are $32.3M, which are smaller than Option Care Health quarterly revenues of $1.3B. OptimizeRx's net income of -$78K is lower than Option Care Health's net income of $60.1M. Notably, OptimizeRx's price-to-earnings ratio is -- while Option Care Health's PE ratio is 26.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx is 1.72x versus 1.14x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.